Pathophysiology and animal models of schizophrenia

Annals of the Academy of Medicine Singapore

Volumn 38, Issue 5, 2009, Pages 425-430

  Dawe, Gavin S ^a   Hwang, Ern Huei Joel ^a   Chay, Hoon Tan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Animal models; Pharmacotherapy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANIMAL MODEL; COGNITIVE DEFECT; DISEASE ASSOCIATION; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR AFFINITY; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYMPTOM;

EID: 67049108714     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. McGrath JJ, Susser ES. New directions in the epidemiology of schizophrenia. Med J Aust 2009;190:S7-9.
2. Maccabe JH. Population-based cohort studies on premorbid cognitive function in schizophrenia. Epidemiol Rev 2008;30:77-83.
3. Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, et al. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry 2008;64:4-10.
4. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003;60:1187-1192 (Pubitemid 37494071)
5. Heydebrand G. Cognitive deficits in the families of patients with schizophrenia. Curr Opin Psychiatry 2006;19:277-281 (Pubitemid 44309485)
6. Joober R, Boksa P, Benkelfat C, Rouleau G. Genetics of schizo phrenia: from animal models to clinical studies. J Psychiatry Neurosci 2002;27:336-347 (Pubitemid 35370373)
7. Grant SG. Synapse signalling complexes and networks: machines underlying cognition. Bioessays 2003;25:1229-1235 (Pubitemid 37499323)
8. Kirov G, O'Donovan MC, Owen MJ. Finding schizophrenia genes. J Clin Invest 2005;115:1440-1448 (Pubitemid 40814648)
9. Owen MJ, Craddock N, O'Donovan MC. Schizophrenia: genes at last? Trends Genet 2005;21:518-525
10. Maier W. Common risk genes for affective and schizophrenic psychoses. Eur Arch Psychiatry Clin Neurosci 2008;258Suppl2:37-40.
11. The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 2008;455:237-241
12. Mulle JG. Genomic structural variation and schizophrenia. Curr Psychiatry Rep 2008;10:171-177
13. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008;320:539-543 (Pubitemid 351590668)
14. Kirov G, Grozeva D, Norton N, Ivanov D, Mantripragada KK, Holmans P, et al. Support for the involvement of large cnvs in the pathogenesis of schizophrenia. Hum Mol Genet 2009;18:1497-1503
15. St Clair D. Copy number variation and schizophrenia. Schizophr Bull 2009;35:9-12.
16. Bellon A. New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. Mol Psychiatry 2007;12:620-629 (Pubitemid 46998253)
17. Tsuang M. Schizophrenia: genes and environment. Biol Psychiatry 2000;47:210-220
18. Flensmark J. Is there an association between the use of heeled footwear and schizophrenia? Med Hypotheses 2004;63:740-747
19. Mittal VA, Ellman LM, Cannon TD. Gene-environment interaction and covariation in schizophrenia: the role of obstetric complications. Schizophr Bull 2008;34:1083-1094
20. Tsankova N, Renthal W, KumarA, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci 2007;8:355-367 (Pubitemid 46652469)
21. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr Psychiatry Rep 2007;9:329-336 (Pubitemid 47490006)
22. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann N Y Acad Sci 2003;1003:138-158 (Pubitemid 38083052)
23. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004;161:398-413. (Pubitemid 38326093)
24. Castagne V, Rougemont M, Cuenod M, Do KQ. Low brain glutathione and ascorbic acid associated with dopamine uptake inhibition during rat's development induce long-term cognitive deficit: relevance to schizophrenia. Neurobiol Dis 2004;15:93-105. (Pubitemid 38134384)
25. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003;169:215-233 (Pubitemid 37264943)
26. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 2007;13:1102-1107 (Pubitemid 47517511)
27. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008;452:93-97 (Pubitemid 351355090)
28. Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berl) 2000;152:283-288
29. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci 2003;1003:318-327 (Pubitemid 38083065)
30. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV. Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 2004;29:208-218 (Pubitemid 38068031)
31. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:1367-1377 (Pubitemid 32847232)
32. McCarley RW, Niznikiewicz MA, Salisbury DF, Nestor PG, O'Donnell BF, Hirayasu Y, et al. Cognitive dysfunction in schizophrenia: unifying basic research and clinical aspects. Eur Arch Psychiatry Clin Neurosci 1999;249 Suppl 4:69-82.
33. Kurachi M. Pathogenesis of schizophrenia: Part I. Symptomatology, cognitive characteristics and brain morphology. Psychiatry Clin Neurosci 2003;57:3-8.
34. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol Behav 2002;77:501-505 (Pubitemid 36084392)
35. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83. (Pubitemid 34786170)
36. Braver TS, Barch DM, Cohen JD. Cognition and control in schizophrenia: a computational model of dopamine and prefrontal function. Biol Psychiatry 1999;46:312-328 (Pubitemid 29335912)
37. Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 2001;50:845-855 (Pubitemid 34020698)
38. Powell SB, Risbrough VB, Geyer MA. Potential use of animal models to examine antipsychotic prophylaxis for schizophrenia. Clin Neurosci Res 2003;3:289-296 (Pubitemid 37461294)
39. Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1071-1079 (Pubitemid 37464953)
40. Powell SB, Geyer MA. Overview of animal models of schizophrenia. Curr Protoc Neurosci 2007;Chapter 9:Unit 9.24.
41. Lipska BK, Weinberger DR. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000;23:223-239 (Pubitemid 30609657)
42. Marcotte ER, Pearson DM, Srivastava LK. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001;26:395-410. (Pubitemid 34082728)
43. Le Pen G, Grottick AJ, Higgins GA, Moreau JL. Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia. Neuropsychopharmacology 2003;28:1799-1809 (Pubitemid 41070845)
44. Meyer U, Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 2008 (In press).
45. Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann N Y Acad Sci 2003;1003:131-137 (Pubitemid 38083051)
46. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997;17:2921-2927 (Pubitemid 27155025)
47. Wiley JL, Buhler KG, Lavecchia KL, Johnson KM. Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:867-873 (Pubitemid 36966770)
48. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999;98:427-436 (Pubitemid 29402481)
49. Hikida T, Jaaro-Peled H, Seshadri S, Oishi K, Hookway C, Kong S, et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A 2007;104:14501-14506 (Pubitemid 350003290)
50. Kvajo M, McKellar H, Arguello PA, Drew LJ, Moore H, MacDermott AB, et al. A mutation in mouse Disc1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci U S A 2008;105:7076-7081 (Pubitemid 351754532)
51. Pletnikov MV, Ayhan Y, Nikolskaia O, Xu Y, Ovanesov MV, Huang H, et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioral abnormalities reminiscent of schizophrenia. Mol Psychiatry 2008;13:173-86,115.
52. Shen S, Lang B, Nakamoto C, Zhang F, Pu J, Kuan SL, et al. Schizophrenia-related neural and behavioral phenotypes in transgenic mice expressing truncated Disc1. J Neurosci 2008;28:10893-10904
53. Brigman JL, Padukiewicz KE, Sutherland ML, Rothblat LA. Executive functions in the heterozygous reeler mouse model of schizophrenia. Behav Neurosci 2006;120:984-988
54. Powell KJ, Hori SE, Leslie R, Andrieux A, Schellinck H, Thorne M, et al. Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci 2007;121:826-835 (Pubitemid 350064351)
55. Dawe GS, Ratty AK. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates. Biotechnol J 2007;2:1344-1352 (Pubitemid 350162255)
56. Torres G, Hallas BH, Vernace VA, Jones C, Gross KW, Horowitz JM. A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia. Brain Res Bull 2004;62:315-326 (Pubitemid 38058312)
57. Fitzgerald LW, Ratty AK, Miller KJ, Ellsworth MK, Glick SD, Gross KW. Ontogeny of hyperactivity and circling behavior in a transgenic insertional mutant mouse. Behav Neurosci 1991;105:755-763
58. Torres G, Meeder BA, Hallas BH, Gross KW, Horowitz JM. Preliminary evidence for reduced social interactions in Chakragati mutants modeling certain symptoms of schizophrenia. Brain Res 2005;1046:180-186 (Pubitemid 40775888)
59. Verma V, Tan CH, Ong WY, Grigoryan GA, Jones CA, Stolzberg D, et al. The chakragati mouse shows deficits in prepulse inhibition of acoustic startle and latent inhibition. Neurosci Res 2008;60:281-288
60. Rosenbaum JF, Arana GW, Hyman SE, Labbate LA, Fava M. Handbook of Psychiatric Drug Therapy. Lippincott Williams & Wilkins, 2005.